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The acidic soluble fraction of whole saliva of type 1 diabetic
children was analyzed by reversed phase (RP)1–HPLC-
ESI-MS and compared with that of sex- and age-matched
control subjects. Salivary acidic proline-rich phospho-
proteins (aPRP), histatins, -defensins, salivary cyst-
atins, statherin, proline-rich peptide P-B (P-B), beta-
thymosins, S100A8 and S100A9*(S100A9* corresponds to
S100A9 vairant lacking the first four amino acids), as well
some naturally occurring peptides derived from salivary
acidic proline-rich phosphoproteins, histatins, statherin,
and P-B peptide, were detected and quantified on the basis
of the extracted ion current peak area. The level of phos-
phorylation of salivary acidic proline-rich phosphoproteins,
histatin-1 (Hst-1), statherin and S100A9* and the percentage
of truncated forms of salivary acidic proline-rich phospho-
proteins was also determined in the two groups. The study
revealed that statherin, proline-rich peptide P-B, P-C pep-
tide, and histatins, were significantly less concentrated in
saliva of diabetic subjects than in controls, while concen-
tration of -defensins 1, 2 and 4 and S100A9* was higher.
The low concentration of P-C peptide was paralleled by
high levels of some of its fragments. On the whole, the
study highlighted the severe impairment of the repertoire
of peptides involved in the safeguard of the oral cavity in
children who have diabetes, as well as an higher concen-
tration of the proinflammatory mediator S100A9* with re-
spect to healthy children. Molecular & Cellular Pro-
teomics 9:2099–2108, 2010.
Type 1 diabetes mellitus is a disease with universal dis-
tribution, affecting all populations (1) with an incidence in-
creasing in Europe (2). Because type 1 diabetes involves
many organs and tissues, signs and symptoms of diabetes
can occur in the oral cavity. Indeed, several studies have
shown that the prevalence, severity, and progression of
periodontal diseases are significantly increased in diabetics,
and the pathology is considered an important risk factor for
periodontitis (3). The study of Lalla et al. (4) showed an
association between diabetes and the increased risk for pe-
riodontal destruction even very early in life. Flow rate and
composition of saliva are crucial for the maintenance of oral
cavity health, and both have been found altered in diabetic
subjects, although with contradictory findings. For instance,
several studies reported a reduced resting salivary flow rate in
adults and children who have type 1 diabetes with respect to
healthy subjects (5–10), but it was also observed that stimu-
lated saliva of diabetics and controls did not significantly differ
(11, 12). Total protein concentration of saliva was found either
increased or not affected by the diabetic status. Lopez et al.
(9) reported higher urea and total protein salivary content in
diabetic children than in controls. Conversely, a study on 35
adult insulin-dependent diabetics demonstrated that they did
not show a decreased saliva concentration of several innate
antimicrobial factors (lysozyme, lactoferrin, salivary peroxi-
dase, myeloperoxidase) and that protein synthesis in salivary
glands, as judged by amylase assays, was within the normal
range (11). In the same study, higher amounts of immuno-
globulin A (IgA) and IgG in diabetics with respect to controls
were detected. Similar results were obtained in type 1 diabetic
children; diabetics had neither salivary total protein nor albu-
min concentrations that were significantly different from con-
trols, however, IgA and IgG levels were increased (12). In a
large study performed in non–insulin-dependent diabetic pa-
tients, a significant increase of the concentration of lacto-
ferrin, myeloperoxidase, and salivary peroxidase in stimulated
parotid saliva, and of total protein, albumin, lactoferrin, and
secretory IgA in stimulated submandibular/sublingual saliva
was shown with respect to controls (13). In the same study it
was also established that submandibular/sublingual salivary
cystatin concentration did not significantly differ between di-
abetics and controls. The finding of increased concentrations
of salivary proteins in diabetics is puzzling given their tend-
ency to be more predisposed to oral infection with respect to
patients who do not have diabetes. In this study we investi-
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gated the composition of the acidic soluble fraction of whole
saliva by RP-HPLC-ESI-MS in a group of children and ado-
lescent diabetics in comparison with a sex- and age-matched
healthy control group. The results highlighted that type 1
diabetes is associated with a deep quali-quantitative modifi-
cation of the salivary peptidome.
EXPERIMENTAL PROCEDURES
Materials—All general chemicals and reagents were of analytical
grade and were purchased from Farmitalia-Carlo Erba (Milan, Italy),
Merck (Darmstadt, Germany), and Sigma-Aldrich (St. Louis, MO).
Subjects—The study protocol and written consent forms were
approved by the Medical Ethics Committee of the Faculty of Medicine
of the Catholic University of Rome (according to the instructions of
the Declaration of Helsinki). The study protocol was explained to both
parents and children, and informed written consent to participate in
the study was obtained from a parent. Diabetic patients were enrolled
at the Pediatric Department of Brotzu Hospital (Cagliari) and controls
at the Department of Surgery and Odontostomatology Sciences of
the Cagliari University. The subjects enrolled were 31 children (22
females and 9 males) aged 11.7  3.6 yr (mean age  S.D.) with
diabetes onset at 5.1  3.3 yr. Percentage of hemoglobin A1c,
determined at the Centro Diabetologico, Brotzu Hospital, Cagliari, by
using the HA8140 Instrument (Menarini diagnostic, Florence, Italy),
was 7.8  0.9% (mean value  S.D.). The control group comprised
the same number of subjects (22 females and 9 males) with the same
mean age 11.7  3.2 yr.
Sample Collection—Whole human saliva was collected according
to a standard protocol. Donors did not eat or drink for 30 minutes
before collection, which was performed between 10:00 am and 12:00
pm. Whole saliva was collected as it flowed into the anterior floor of
the mouth with a soft plastic aspirator for less than one minute and
transferred to a plastic tube. An acidic solution (0.2% TFA) was
immediately added to salivary samples in ice bath in 1:1 v/v ratio and
the solution centrifuged at 8,000 g at 4 °C for five minutes. The acidic
supernatant was separated from the precipitate and either immedi-
ately analyzed by the HPLC-ESI-MS apparatus (100 L, correspond-
ing to 50 L of saliva) or stored at - 80 °C until the analysis.
HPLC-ESI-IT-MS Analysis—The HPLC-ESI-MS apparatus was a
Surveyor HPLC system (ThermoFisher, San Jose, CA) connected by
a T splitter to a photodiode array detector and the electrospray
ionization/ion trap mass spectrometer LCQ Deca XP Plus (Ther-
moFisher). The chromatographic column was either a Vydac (Hes-
peria, CA) C8 with a 5-m particle diameter (column dimensions
150  2.1 mm), or a Vydac C18 with 5-m particle diameter
(column dimensions 150  2.1 mm), the latter used for the analysis
of the digestion products of S100A9* isoforms. The following solu-
tions were used for RP-HPLC-ESI-MS analysis: (eluent A) 0.056%
(v/v) aqueous TFA and (eluent B) 0.05% (v/v) TFA in acetonitrile-
water 80/20, and the flow rate was 0.30 mL/min. Salivary proteins
were eluted using a linear gradient from 0 to 55% of B in 40
minutes, whereas for tryptic digests the gradient was from 0 to 65%
of B in 40 minutes, and from 65% to 100% of B in five minutes. The
T splitter permitted 0.20 mL/min to flow toward the diode array
detector and 0.10 mL/min to flow toward the ESI source. During the
first five minutes of the RP-HPLC separation, eluate was not ad-
dressed toward the MS apparatus to avoid instrument damage
deriving from the high salt content. The photodiode array detector
was set at 214 and 276 nm. Mass spectra were collected every
three milliseconds in the positive ion mode. The MS spray voltage
was 4.50 kV, the capillary temperature was 220 °C.
High-ResolutionHPLC-ESI-MSExperiments—High resolutionHPLC-
ESI-MS and MS/MS experiments were performed using an Ultimate
3000 Nano/Micro-HPLC apparatus (Dionex, Sunnyvale, CA) equipped
with an FLM-3000-Flow manager module, and coupled to an LTQ
Orbitrap XL hybrid mass spectrometer (ThermoFisher), having a nano
ESI source (Proxeon Biosystems, Odense, Denmark). Separations were
performed by a Dionex 18 column (3-m particle diameter; column
dimension 300 m i.d. 15 cm), using the following eluents: (A) 0.05%
(v/v) aqueous TFA and (B) 0.05% (v/v) TFA in acetonitrile. The applied
gradient was 0–4 min 5% B, 4–34 minutes from 5 to 50% B (linear),
34–64 minutes from 50 to 90% B (linear), at a flow rate of 4.5 L/min.
High-resolution positive MS spectra were collected in full scan mode
and in data-dependent acquisition mode, using the lock mass for inter-
nal mass calibration (polydimethyl cyclosiloxane, 445.1200m/z) with the
resolution of 60,000 and 30,000, respectively, andm/z range 350–2000.
The three most intense multiply charged ions were selected and frag-
mented by using collision induced dissociation (35% normalized colli-
sion energy) and spectra were recorded in the Orbitrap. Tuning param-
eters were: capillary temperature 220 °C, source voltage 2.4 kV,
capillary voltage 26 V, and tube lens voltage 245 V.
Characterization of Salivary Peptides and Proteins—Proteins (sali-
vary acidic proline-rich phosphoproteins, histatins, -defensins, sal-
ivary cystatins, statherin, proline-rich peptide P-B, and beta-thy-
mosins) and naturally occurring peptides derived from salivary acidic
proline-rich phosphoproteins, histatins, statherin, and P-B peptide
have been already identified in previous studies (14–19). Character-
ization of salivary proteins and peptides followed a top down ap-
proach. The accurate mass measurement of intact pure proteins/
peptides (or semi-purified fractions) made it possible also to identify
multiple forms of post-translational modification products. Structural
characterization was based on tandem-MS analysis and automated
amino acid sequencing of entire proteins, as well as of proteolytic
fragments obtained after different enzymatic treatments of pure pro-
teins. Deconvolution of averaged ESI-MS spectra was automatically
performed using either the Bioworks Browser software provided with
the LCQ Deca XP instrument or MagTran 1.0 software (20). Experi-
mental mass values were compared with the theoretical ones found in
Swiss-Prot Data Bank (http://us.expasy.org/tools) given the acces-
sion numbers listed in Tables I and II.
To confirm the structure of the salivary proteins and fragments not
previously characterized by us, some samples were also submitted to
high-resolution HPLC-ESI-MS/MS experiments (LTQ Orbitrap XL), ac-
cording to the conditions above reported. Tandem-MS spectra were
analyzed by the Proteome Discoverer 1.0 program, based on SEQUEST
cluster as search engine (University of Washington, Seattle, licensed to
Thermo Electron Corp., San Jose, CA) against the Swiss-Prot human
proteome (March 10, 2010, release; uniprot-taxonomy-9606-AND-re-
viewed-yes.fasta; 34756 non redundant protein sequences). The follow-
ing limits were used for peptide matching: Xcorr scores greater than 1.5
for singly charged peptide ions and 2.0 and 2.5 for doubly and triply
charged ions, respectively, one missed cleavage site. Sequences were
also confirmed by manual comparison of experimental MS/MS spectra,
obtained by using the program Extract_msn (ThermoFisher) and default
parameters, with the theoretical spectra generated using the MS-Prod-
uct program available at the Protein Prospector site (http://us.expasy-
.org/tools). The match was considered positive when all the experimen-
tal m/z values with a relative abundance higher than 10% were present
in the theoretical fragmentation spectrum and when the differences
between the experimental and theoretical values were less than 0.03
m/z in high-resolution MS/MS spectra. Annotated MS/MS spectra are
reported as supplemental material. Structures of S100A9* and deriv-
atives were also confirmed by trypsin digestion and low resolution
HPLC-ESI-MS/MS analysis of digestion mixture.
Trypsin Digestion of S100A9* and Derivatives—S100A9* isoforms
were isolated from a salivary sample by preparative RP-HPLC using a
preparative Vydac C8 Column (250  10 mm 5 m), a flow rate of 2.8
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mL/min, and the following eluents: (eluent A) 0.056% (v/v) aqueous
TFA and (eluent B) 0.05% (v/v) TFA in acetonitrile-water 80/20. The
gradient was from 0% to 60% of B in 37 minutes and from 60% to
100% B in 12 minutes. The chromatographic peak eluting at 68% of
B, collected and analyzed by HPLC-ESI-MS, corresponded to the
mixture of S100A9* isoforms. Lyophilized sample was submitted to
digestion by using the kit “Trypsin Singles Proteomic Grade” (Sigma-
Aldrich) according to the manufacturer instructions. The reaction was
stopped with TFA (0.1% final concentration) after six hours of incu-
bation and analyzed by RP-HPLC-ESI-MS, as above reported. RP-
HPLC-ESI-MS analysis showed the presence of four different frag-
ments 89–109 (T12). Three of them were submitted to tandem-MS
analysis, performed on the triply charged ions at 726.40 m/z, 731.53
m/z, and 752.87 m/z (see supplemental material). The intensity of the
fourth T12 peptide did not allow sequencing. Isolation width of 3.0
m/z, normalized collision energy of 50%, activation Q of 0.25 and
activation time of 30 milliseconds were applied. Experimental MS/MS
spectra were compared with the theoretical spectra generated using
the MS-Product program available at the Protein Prospector site
(http://us.expasy.org/tools). The match was considered positive when
all the experimental m/z values with a relative abundance higher than
10% were present in the theoretical fragmentation spectrum and
when the differences between the experimental and theoretical values
were less than  0.5 m/z.
Quantification—Quantification was based on the area of the RP-
HPLC-ESI-MS extracted ion current (XIC) peaks, considered when
the signal-to-noise ratio was at least 5. Under constant analytical
conditions, the area of the XIC peaks is proportional to the peptide/
protein concentration (21, 22). The XIC analysis selectively reveals a
protein in the chromatographic profile by extracting the ion current
associated with the multiply charged ions characteristic of the pro-
tein. The ions used to quantify the proteins/peptides were carefully
selected to exclude values in common with other co-eluting proteins,
and, with the exception of S100A8 and S100A9* isoforms and the
new fragments characterized in this work, they were reported previ-
ously (16, 19, 23). The following ions were used to quantify S100A8
and S100A9* isoforms: S100A8, 985.9 (11), 1084.4 (10), 1204.8
(9), and 1355.3m/z (8); S100A9* nonphosphorylated, 977.2 (13),
1058.5 (12), 1154.6 (11), 1270.0 (10), 1411.0 (9); S100A9*
phosphorylated, 983.3(13), 1065.2 (12), 1161.9 (11), 1278.0
(10), 1419.9 (9); S100A9* nonphosphorylated oxidized, 978.4
(13), 1059.8 (12), 1156.1 (11), 1271.6 (10), 1412.8 (9);
S100A9* phosphorylated oxidized, 984.5 (13), 1066.5 (12), 1163.4
(11), 1279.6 (10), 1421.7 (9). Percentages of monophosphory-
lated statherin, nonphosphorylated Hst-1, monophosphorylated
aPRP-1 type proteins and nonphosphorylated S100A9* (oxidized
plus not oxidized) were calculated on the basis of the following XIC
peak area ratios: percentage of monophosphorylated statherin 
100  monophosphorylated statherin/(monophosphorylated
statherin  2  diphosphorylated statherin), percentage of nonphos-
phorylated Hst-1  100  nonphosphorylated Hst-1/(monophos
Hst-1  nonphosphorylated Hst-1), percentage of monophosphory-
lated aPRP-1 type proteins  100  monophosphorylated proline-rich
phosphoprotein (PRP)–1/(monophosphorylated PRP-1 2 diphos-
phorylated PRP-1  3  triphosphorylated PRP-1), and percentage
of nonphosphorylated S100A9*  100  nonphosphorylated
S100A9*/(monophosphorylated S100A9*  nonphosphorylated
S100A9*) (nonphosphorylated and monophosphorylated forms
comprised both oxidized and not oxidized derivatives). The percent-
age of truncated aPRPs (PRP-3 types; see Table I for definition) was
calculated on the basis of the following XIC peak area ratio: 100 
(total PRP-3 types)/(total PRP-3 types  total PRP-1 types).
Data Analysis—The software GraphPad Prism (version 4.0) was
used for statistical analysis. Ranges, medians, means, standard de-
viations, and standard errors were calculated for all the peptides/
proteins XIC peak area. Means and standard errors are reported in
Tables III and IV. Standard errors take into account both the value of
standard deviation and sample size and are shown to give the pre-
cision on population means. The non-parametric Mann-Whitney test
was used to compare the two groups. Statistical analysis was con-
sidered significant when the p value was less than 0.05 (two-tailed).
RESULTS
According to the guidelines for the management of type 1
diabetes mellitus (24) and on the basis of hemoglobin A1c
levels less than 9.9% the group of diabetics enrolled for the
study comprised well-to-moderately controlled patients.
For ethical reasons it was not possible to collect selected
saliva from gland ducts of the young donors, thus, the
present study was performed on whole saliva. However,
contribution of the submandibular/sublingual glands was
slightly higher than parotid glands because saliva was col-
lected from the floor of the mouth close to orifices of Whar-
ton’s ducts. HPLC-ESI-MS analysis of whole human saliva
allows detecting more than 120 salivary components (25). In
the present study, we investigated the following already
characterized salivary proteins: salivary acidic proline-rich
phosphoproteins, histatins, -defensins, salivary cystatins
(Table I), statherin, proline-rich peptide P-B, and beta-thy-
mosins (Table II), as well as several derivatives generated by
post-translational modifications occurring before and after
secretion, such as phosphorylated isoforms and cleavage
products. We also detected and quantified some proteins
belonging to the S100 family, not previously evidenced in
saliva by the HPLC-ESI-MS approach. They were S100A8
and four different forms of S100A9*. The chromatographic
position of these calcium binding proteins is evidenced in
Figure 1. The figure shows that the four isoforms of S100A9*
co-eluted. Two of them corresponded to S100A9* nonphos-
phorylated and phosphorylated at Thr-108 (26). The remaining
two isoforms were the corresponding oxidized derivatives
(mass  16.0 Da). Structure of S100A8 and S100A9* were
confirmed by tandem-MS experiments (annotated spectra are
reported as supplemental material). The structures of
S100A9* and its phosphorylated, oxidized, and phosphoryla-
ted-oxidized derivatives were confirmed by peptide mapping
analysis. The results of RP-HPLC-ESI-MS analysis of the
tryptic digestion mixture of the four isoforms, as well as tan-
dem-MS spectra of the tryptic fragment T12, carrying the
modifications, were in agreement with the assigned structures
and allowed to locate the phosphorylation at Thr-108 residue
and oxidation at Met-89 residue (annotated spectra are re-
ported as supplemental material).
Quantitation and Comparison of Salivary Peptide Levels
Between Diabetics and Controls—The acidic treatment with
aqueous TFA, performed immediately after collection to min-
imize protein degradation, caused precipitation of a pellet
mainly constituted by high molecular weight proteins. As pre-
viously shown, precipitation did not affect significantly the
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quali/quantitative profile of acid-soluble proteins (23). Levels
of salivary proteins and naturally occurring peptides were
determined by HPLC-ESI-MS analysis, and the typical chro-
matographic profile obtained under our experimental condi-
tions in the two groups under study is shown in Figure 1.
Mann-Whitney test of the XIC peak areas revealed that
statherin (diphosphorylated and monophosphorylated), pro-
line-rich peptide P-B, P-C peptide, Hst-1, and nonphosphor-
ylated Hst-1 were significantly less concentrated in saliva of
diabetic patients than in controls, whereas the levels of -de-
fensins 1, 2, and 4 were significantly lower in saliva of control
subjects (Table III). We also found that concentration of phos-
phorylated S100A9* (sum of oxidized and not oxidized forms)
was significantly higher in diabetics than in controls (p 
0.004). The same result was obtained considering the totality
of S100A9*forms (p  0.01). Conversely, S100A8 levels were
not significantly different in the two groups (p  0.28). The
reduced concentration of P-C peptide was intriguing because
neither the level of PRP-1 type proteins, from which P-C
peptide is originated by a pre-secretory cleavage, nor the
level of the complementary fragments (PRP-3 type proteins),
was significantly different in the two groups under investiga-
tion. To establish whether quantitative differences between
diabetics and controls could be related to a different degree of
proteolytic fragmentation occurring in the oral cavity, we
searched for masses not yet characterized in the chromato-
graphic profile of saliva of diabetics. Several masses were
detected in the elution range of 5–30 minutes. Masses spo-
radically revealed were not further investigated, those de-
tected in at least 9 of 31 samples were also searched in saliva
chromatographic profile of controls, and quantified. The anal-
ysis by Mann-Whitney test of the XIC peak areas showed that
14 peptides were significantly more concentrated in saliva of
diabetics than in controls (Table IV). The primary structure of
these peptides (Table V) was determined by selected ion
monitoring MS/MS experiments. Seven of them corre-
sponded to the following fragments of P-C peptide: P-C pep-
tide fr. 1–14 (exptl av mass: 1470.8 Da), P-C peptide fr. 1–25
(exptl av mass: 2521.4 Da), P-C peptide fr. 5–25 (exptl av
mass: 2083.3 Da), P-C peptide fr. 26–44 (exptl av mass:
1867.2 Da), P-C peptide fr. 26–35 (exptl av mass: 990.1 Da),
P-C peptide fr. 36–44 (exptl av mass: 894.9 Da), P-C peptide
fr. 15–44 (exptl av mass: 2917.4 Da). Two peptides corre-
sponded to fragment 94–105 of PRP-1/PRP-3 type proteins
and 94–110 of PRP-1 type proteins. These two fragments
accounted for approximately 0.8% of intact PRP-1/PRP-3
TABLE I
Elution times, experimental and theoretical average mass values (Da) of salivary acidic Proline-rich Phosphoproteins, Histatins, -Defensins,
Salivary Cystatins and derivatives
Protein (Swiss-Prot code or ref.) Elution time (min) Experimental av mass (theoretical av mass)
Salivary acidic proline-rich phosphoproteinsa
PRP-1 type diphos (P02810) 22.9–23.3 15515  2 (15514–15515)
PRP-1 type monophos (P02810) 23.9–24.3 15435  2 (15434–15435)
PRP-1 type triphos (P02810) 22.6–22.9 15595  2 (15594–15595)
PRP-3 type diphos (P02810) 23.3–23.8 11161  1 (11161–11162)
PRP-3 type monophos (P02810) 23.8–24.2 11081  1 (11081–11082)
PRP-3 type diphos Des-Arg106 (P02810) 23.5–23.8 11004  1 (11005–11006)
P-C peptide (P02810) 13.6–14.5 4370.9  0.4 (4370.8)
P-C peptide Des-Gln44 (25) 13.8–14.4 4242.7  0.4 (4243.0)
Histatins
Hst-1 (P15515) 23.3–23.8 4928.2  0.5 (4928.2)
Hst-1 nonphos (P15515) 23.4–23.8 4848.2  0.5 (4848.2)
Hst-3 (P15516) 17.6–17.9 4062.2  0.4 (4062.4)
Hst-3 1/24 (P15516) 14.2–14.7 3036.5  0.3 (3036.3)
Hst-3 1/25 (P15516) 14.0–14.4 3192.4  0.3 (3192.5)
-Defensins
-defensin 1 (P59665) 23.2–24.2 3442.1  0.4 (3442.1)
-defensin 2 (P59665 and P59666) 23.2–24.2 3371.0  0.4 (3371.0)
-defensin 3 (P59666) 23.2–24.2 3486.1  0.4 (3486.1)
-defensin 4 (P12838) 27.0–27.7 3709.4  0.5 (3709.5)
Salivary cystatins (17)
S nonphos (P01036) 36.5–37.1 14186  2 (14185)
S monophos at Ser3 (P01036) 36.6–37.1 14266  2 (14265)
S diphos at Ser1 and Ser3 (P01036) 36.8–37.2 14346  2 (14345)
SN (P01037) 34.8–35.2 14312  2 (14313)
SA (P09228) 38.4–38.9 14347  2 (14346)
a The term PRP-1 type includes the three entire isoforms PRP-1, PRP-2, and Pif-s, with a mass difference of 1 Da. The term PRP-3 type
includes the truncated isoforms PRP-3, PRP-4 and Pif-f (Ref. 14).
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type proteins. The low extent of fragmentation is in agreement
with the lack of significant differences in the XIC peak areas
of acidic PRPs between diabetics and controls. Although
the last five fragments have not been identified, MS/MS
spectra allowed an origin from salivary secretory peptides/
proteins to be excluded. Differently from P-C peptide, the
lower concentration of statherin in saliva of diabetics with
respect to controls (p  0.0001, Table III) was not paralleled
by an higher concentration of statherin fragments, and rather
the level of statherin Des1–9, a fragment generated by a pre-
secretory cleavage, was found to be lower in diabetics (p 
0.003). Serine phosphorylation level of statherin, Hst-1, and
aPRPs, evaluated by the percentages of monophosphoryla-
ted statherin, nonphosphorylated Hst-1, and monophosphor-
ylated aPRPs (entire isoforms), did not show significant dif-
ferences in the two groups under study. Conversely, the
percentage of total nonphosphorylated S100A9* (oxidized
plus not oxidized) was significantly lower in the patient
group (diabetics: 55.0  3%, controls: 72.5  4.5%, p 
0.0006). At this regard, it is relevant to outline that the site of
phosphorylation of S100A9* is a threonine. The percentage
of truncated salivary acidic proline-rich phosphoproteins
did not show significant differences in the two groups under
study.
DISCUSSION
In a previous work devoted to the investigation of the influ-
ence of the age on salivary protein composition, we evi-
denced that the expression of basic PRPs is age-related and
that these salivary proteins reach the concentration found in
adults only after puberty (12–17 years of age) (23). Since the
age of the subjects enrolled for this study was comprised
between 7–18 years, basic PRPs (bPRPs) were not consid-
ered in the present investigation.
This study revealed that protein composition of saliva of
diabetic patients is different from that of sex- and age-
matched controls, both from a qualitative and from a quan-
titative point of view. Statherin, proline-rich peptide P-B,
P-C peptide, and Hst-1, were found significantly less con-
centrated in saliva of diabetics, whereas -defensins 1, 2, and
4, S100A9* and several small peptides, most likely originated
by post-secretory proteolytic cleavages occurring in the
mouth, showed a higher concentration.
Tandem-MS experiments allowed establishing that these
peptides were mainly represented by P-C peptide fragments.
Fragments 1–14, 1–25, 5–25, 26–35, 26–44, and 36–44 of
P-C peptide have been already detected in saliva from healthy
subjects (27). An association of fragments 1–14 and 26–44 to
TABLE II
Elution times, experimental and theoretical average mass values (Da) of statherin, proline-rich peptide P-B, beta-thymosins, S100A8,
S100A9* proteins and derivatives
Protein (Swiss-Prot code
or reference number)
Elution time (min) Experimental av mass (theoretical av mass)
Statherin and derivatives
statherin diphos (P02808) 28.9–29.5 5380.0  0.5 (5379.7)
statherin monophos (18) 28.7–29.1 5299.9  0.5 (5299.7)
statherin nonphos (18) 28.4–28.8 5220.5  0.5 (5219.7)
SV1 (statherin Des-Phe43) (18) 27.6–28.0 5232.4  0.5 (5232.5)
statherin Des-Thr42Phe43 (18) 27.7–28.1 5131.2  0.5 (5131.4)
statherin Des-Asp1 (18, 51) 28.5–28.9 5264.7  0.5 (5264.6)
statherin Des1–9 (18) 27.5–28.8 4127.9  0.4 (4127.6)
statherin Des1–10 (18) 27.8–28.2 3971.3  0.4 (3971.4)
statherin Des1–13 (18) 27.8–28.3 3645.2  0.4 (3645.0)
Proline-rich peptide P-B and derivatives
P-B (P02814) 29.4–30.5 5792.9  0.5 (5792.7)
P-B Des1–5 (18) 29.9–30.7 5215.0  0.5 (5215.1)
P-B Des1–7 (23) 29.6–30.5 5061.7  0.5 (5060.9)
P-B Des1–4 (23) 29.6–30.2 5370.7  0.5 (5371.3)
P-B Des1–12 (23) 27.2–27.7 4549.4  0.5 (4549.3)
Thymosins (19)
Thymosin 4 (P62328) 20.7–21.0 4963.7  0.4 (4963.5)
Thymosin 10 (P63313) 21.7–22.2 4936.8  0.4 (4936.5)
Thymosin 4 sulfoxide 18.0–18.5 4979.7  0.4 (4979.5)
S100A proteins
S100A8 (P05109) 38.8–39.4 10832.2  1 (10834.5)
S100A9* monophos (P06702) 41.4–42.1 12770.2  1 (12769.2)
S100A9* monophos ox 41.4–42.1 12786.5  1 (12785.2)
S100A9* nonphos (P06702) 41.4–42.1 12690.1  1 (12689.2)
S100A9* nonphos ox 41.4–42.1 12706.9  1 (12705.2)
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high numbers of dental caries and the presence of fragment
1–14 in saliva of subjects affected by Sjogrens syndrome
were also reported (28). The same authors also detected
fragments 1–25 and 15–44 in whole saliva of normal subjects,
whereas fragments 1–14 e 26–44 were found in parotid saliva
in another study (29). The higher concentration of P-C frag-
ments in diabetics is consistent with the observed decreased
concentration of the intact peptide. This finding suggests that
the low concentration of P-C peptide should not reflect a
lower activity of the pro-protein convertases acting on aPRPs
before secretion, and generating P-C peptide and the com-
plementary PRP-3 type proteins. Indeed, we did not find any
significant difference in salivary concentration of PRP-1 type
proteins and PRP-3 type proteins between diabetics and
controls. Fragmentation of P-C peptide, occurring mainly at
the XPQ2G site (where X is preferably K, but often S and R),
seems to be related to a glutamine endoprotease activity
probably of microbial origin, as reported by Helmerhorst et al.
(27). Our data suggest that in the oral environment of diabetic
subjects the activity of this proteolytic enzyme could be higher
FIG. 1. Typical RP-HPLC-ESI profile
of the acidic soluble fraction of hu-
man whole saliva of a control subject
(A) and a Type 1 diabetic patient (B).
Elution ranges of the principal classes
of human salivary proteins/peptides are
indicated. The other panels show the
extracted ion current (XIC) peaks of
nonphosphorylated S100A9* (C), phos-
phorylated S100A9* (D), nonphosphory-
lated oxidized S100A9* (E), phosphory-
lated oxidized S100A9* (F), and S100A8
(G).
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than in healthy subjectsl. A reduced concentration of P-C pep-
tide in saliva of type 2 diabetics with respect to healthy subjects
has been reported by Kimura et al. (30). Low concentration of
P-C peptide in saliva of diabetics is particularly intriguing and
stimulates further deep studies, in consideration of its potenti-
ating effect on glucose and arginine induced insulin release
shown in vitro in perfused rat pancreas (31).
Differently from P-C peptide, the lower concentration of
statherin and statherin Des1–9, a fragment of pre-secretory
origin, were not paralleled by higher concentrations of other
post-secretory fragments in saliva of diabetics. Thus, it may
be hypothesized that the low concentration might be con-
nected either to a different degree of statherin expression in
salivary glands of diabetics or to the recruitment of this pep-
tide to accomplish specific roles in the oral cavity of diabetics.
In this regard, it is known that statherin, a tyrosine-rich 43
residue phosphopeptide involved in oral calcium homeostasis
and teeth mineralization (32), is an in vivo constituent of the
human acquired enamel pellicle (33). This protein film is im-
portant for the integrity of tooth enamel because it acts as a
boundary lubricant on the enamel surface (34), and it has been
shown that interactions between pellicle proteins and bacte-
rial surfaces are responsible for specificity of the bacterial
colonization during the earliest stage of plaque formation (35).
Similar to statherin, P-B peptide showed low levels in saliva of
diabetics. P-B peptide is usually included into the basic proline-
rich protein family. However, unlike other bPRPs it is not a
generated by the proteolytic cleavage of a larger pro-protein,
but it is a mature protein itself, expressed by PROL3 gene
located on chromosome 4q13.3, very close to STATH gene (36).
P-B peptide shares more structural similarities with statherin.
Similar to statherin, it is secreted both from parotid and sub-
mandibular/sublingual glands and the correlation between the
two peptides in whole saliva is highly significant (18).
Also, in the case of Hst-1, the low levels found in saliva of
diabetic patients should not be related only to a different
degree of fragmentation of the peptide, which was shown to
be almost stable in the environment of the oral cavity (37).
Indeed, fragments of Hst-1 were not significantly more repre-
sented in saliva of diabetics than in controls. Recently it has
been shown that Hst-1 plays an important role in the oral
cavity because of its wound healing properties (38). The lower
concentration of Hst-1 indicates that this role could not be
fully achieved in the mouth of diabetics. It has been also
reported that Hst-3 1/24 (Hst-5) displays the highest antifun-
gal activity among the histatins (39), and it has been shown
that it is an inhibitor of both host and bacterial enzymes
implicated in periodontal disease (40).
In our study we showed that salivary levels of the major
-defensins are higher in diabetics than in controls. This result
is in agreement with literature data. In fact, Seraheimo et al.
(41) observed that -defensin (1, 2, and 3) levels were in-
creased in a group of type 1 diabetic patients with nephrop-
athy with respect to normoalbuminuric patients. Otherwise,
plasma defensin levels of the latter group were approximately
five times higher than non-diabetics, which had -defensins
serum level of approximately 120 g/L (42). Thus, saliva re-
flects plasma concentration of -defensins. This finding is of
particular interest in consideration of the study of Joseph et al.
(43) that not only confirmed the higher -defensin levels in
type 1 diabetic patients with than without microalbuminuria,
TABLE III
Families of salivary peptides showing different extracted ion current
peak areas between diabetics and controls. Mean value  S.E. (106)
Peptide or derivative Diabetics Controls p value
Statherin diphos 190  26 590  67 0.00012
Statherin monophos 4.1  0.7 12.0  1.4 0.00012
Statherin nonphos 0.5  0.2 2.8  0.9 0.0042
Statherin Des-Phe43 (or SV1) 20.7  3.1 22.9  3.5 Ns
Statherin Des-Thr42-Phe43 12.4  2.8 8.4  1.3 Ns
Statherin Des-Asp1 18.9  2.7 20.9  3.3 Ns
Statherin Des1–9 14.2  2.2 30.6  6.1 0.0032
Statherin Des1–10 8.7  1.3 10.8  1.7 Ns
Statherin Des1–13 5.2  0.8 7.7  1.4 Ns
P-B 177  29 411  57 0.00012
P-B Des1–4 23.3  3.2 19.1  4.2 Ns
P-B Des1–7 42.1  5.5 79.5  10.0 0.00052
P-B Des1–12 26.9  4.8 23.8  4.9 Ns
P-C peptide 189  30 417  87 0.00082
P-C peptide Des-Gln44 4.3  1.8 8.5  2.1 0.0042
Hst-1 91.6  14.9 288.3  44.9 0.00012
Hst-1 nonphos 14.8  3.1 49.7  8.2 0.00012
Hst-3 25.4  5.9 51.3  13.0 0.032
Hst-3 1/24 68.6  12.6 135.7  32.3 0.042
Hst-3 1/25 27.7  4.6 48.7  10.4 Ns
a-defensin 1 48.0  7.2 25.6  5.5 0.0071
a-defensin 2 34.2  5.1 22.1  4.4 0.021
a-defensin 4 8.2  1.3 4.3  1.1 0.011
S100A9* totala 91.2  13.6 58.6  15.2 0.011
S100A9* phosb 40.2  6.3 21.4  6.2 0.0041
S100A8 18.2  3.8 12.7  3.8 Ns
The arrow shows the variation of diabetics vs. controls. a The four
isoforms of S100A9*. b The two isoforms oxidized and not oxidized.
Ns: not significative.
TABLE IV
Extracted ion current peak area (mean value  S.E. (107)) of new
fragments of salivary peptides and proteins showing a significant
different concentration between diabetics and controls
Peptide fragment Diabetics Controls p value
P-C peptide fr. 1–14 1.3  0.3 0.7  0.2 0.0011
P-C peptide fr. 1–25 2.2  0.3 1.3  0.3 0.0031
P-C peptide fr. 5–25 2.4  0.4 1.1  0.4 0.021
P-C peptide fr. 15–44 1.3  0.2 0.7  0.2 0.0021
P-C peptide fr. 26–35 4.5  0.8 2.4  0.7 0.011
P-C peptide fr. 26–44 1.5  0.2 0.7  0.2 0.0041
P-C peptide fr. 36–44 8.1  1.1 4.1  1.0 0.0021
PRP-1/PRP-3 fr. 94–105 1.2  0.2 0.5  0.1 0.00031
PRP-1 fr. 94–110 0.4  0.07 0.07  0.02 0.00011
N.I. peptide 559.3 Da 0.2  0.1 0.1  0.02 0.031
N.I. peptide 1237.7 Da 1.3  0.3 0.4  0.1 0.021
N.I. peptide 1238.4 Da 1.5  0.2 0.7  0.2 0.00051
N.I. peptide 2542.3 Da 0.9  0.2 0.4  0.1 0.041
N.I. peptide 2485.9 Da 0.8  0.1 0.4  0.1 0.0161
The arrow shows the variation of diabetics vs. controls.
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but also suggested that plasma -defensins may serve as
clinical risk marker for cardiovascular morbility and mortality
in these patients.
Also, concentration of S100A9* was higher in saliva of
diabetics than in controls. S100A9 represents 45% of the
cyplasmatic fraction of neutrophils together with S100A8 un-
derlining its importance in inflammation (44). Extracellularly its
function includes chemotactic activity, triggering local inflam-
mation, regulation of adhesion, transendothelial migration of
leukocytes, and striking antimicrobial activity (45). The level of
S100A8 did not increase along with S100A9, even though the
two proteins are frequently co-expressed and can form a
noncovalent heterodimer protein complex (calprotectin) which
antagonizes the monomer function (46). However, Bouma et
al. also observed increased levels of S100A9 and S100A8/
S100A9 heterodimer, but not of S100A8, in sera of type 1
diabetic patients and showed that this variation is specific of
this subtype of diabetes (47). Thus, the present data suggest
that saliva and serum concentrations of the two calcium bind-
ing proteins correlate.
The proteolytic cleavages occurring before secretion did
not show significant differences in the two groups under
study, suggesting that the activity of the involved pro-protein
convertases is not affected by the pathology.
Different results were obtained on phosphorylation levels.
In fact, phosphorylation of serine residues, such as those
present in aPRPs, statherin, and Hst-1, showed a similar
extent in diabetics and controls, suggesting that the dia-
betic status should not affect the activity of the Golgi-casein
kinase involved in the pre-secretory phosphorylation of ser-
ine residues. Conversely, phosphorylation level of S100A9*
was higher in diabetic subjects. In this regard, it is relevant
to outline that the site of phosphorylation of S100A9* is
represented by a threonine residue, and that the phophory-
lation is under the control of p38 MAPK pathway (48). It has
been suggested that phosphorylation of S100A9 by p38
MAPK contributes to p38 MAPK regulation of cytoskele-
tal reorganization necessary for exocytosis (48). Moreover,
it has been reported an increased phosphorylation of
S100A9* during human neutrophil activation (49) and that
the phosphorylation event is connected with the regulation
of translocation of the peptide to the plasma membrane.
The present data are in agreement with the increased mono-
cytic activity and with the increased expression of pro-
inflammatory mediators observed in patients who have type
1 diabetes (50).
CONCLUSION
Collectively, our findings highlight that quantitative and
qualitative differences occur in the salivary peptidome of type
1 diabetic subjects, with particular regard to peptides involved
in inflammation and oral cavity host defense. The increased
levels of several proteolytic fragments of P-C peptide in dia-
betics indicate a possible variation of exogenous proteinases
in the oral cavity of diabetics. This observation is a stimulus
for further studies to establish a possible connection between
peptide fragments and oral microflora in diabetics. The de-
creased concentration of statherin, P-B peptide, and histatins
suggests to verify if the low concentration of these peptides
may contribute to the major incidence of dental and periodon-
tal diseases in the type 1 diabetic population, possibly allow-
ing the formulation of specific aids for their oral health.
The present results provide the basis for further studies on
large cohorts of diabetic subjects to discover potential sali-
vary biomarkers, which should be extensively validated by
antibody-based methods, such as ELISA or Western blot.
Thus, new and noninvasive tests might be developed for
monitoring type 1 diabetes complications.
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TABLE V







m/z values of multiply charged
ions used to reveal XIC peaks Sequence
P-C peptide fr. 1–14 (P02810) 8.5–8.9 1470.8  0.4 (1471.6) 1471.8 (1), 736.4 (2) GRPQGPPQQGGHQQ
P-C peptide fr. 1–25 11.6–12.0 2521.4  0.4 (2521.8) 1261.9 (2), 841.6 (3) GRPQGPPQQGGHQQGPPPPPPGKPQ
P-C peptide fr. 5–25 11.1–11.5 2083.3  0.4 (2083.3) 1042.6 (2), 695.4 (3) GPPQQGGHQQGPPPPPPGKPQ
P-C peptide fr.15–44 12.3–12.8 2917.4  0.4 (2917.2) 1459.7 (2), 973.5 (3) GPPPPPPGKPQGPPPQGGRPQGPPQGQSPQ
P-C peptide fr. 26–35 7.9–8.5 990.1  0.3 (990.1) 991.1 (1), 496.1 (2) GPPPQGGRPQ
P-C peptide fr. 26–44 9.2–9.8 1867.2  0.4 (1867.0) 934.6 (2), 623.4 (3) GPPPQGGRPQGPPQGQSPQ
P-C peptide fr. 36–44 6.5–7.3 894.9  0.3 (894.9) 895.9 (1), 448.5 (2) GPPQGQSPQ
PRP-1/PRP-3 fr. 94–105 (P02810) 10.8–11.3 1223.8  0.4 (1224.4) 1224.8 (1), 612.9 (2) GPPQQGGHPRPP
PRP-1 fr. 94–110 10.7–11.5 1818.9  0.4 (1819.0) 910.5 (2), 607.3 (3) GPPQQGGHPRPPRGRPQ
N.I. 6.6–7.3 559.3 560.3 (1)
N.I. 12.0–12.5 1237.7 1238.7 (1), 619.9 (2)
N.I. 12.7–13.4 1238.4 1239.4 (1), 620.2 (2)
N.I. 25.0–25.5 2542.3 1272.2 (2), 848.4 (3)
N.I. 19.0–19.6 2485.9 1244.0 (2), 829.6 (3)
N.I.: not identified.
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